BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

British Journal of Radiology (2003) 76, S50-S59
© 2003 British Institute of Radiology
doi: 10.1259/bjr/30399077

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laking, G R
Right arrow Articles by Price, P M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laking, G R
Right arrow Articles by Price, P M

Full Paper

Positron emission tomographic imaging of angiogenesis and vascular function

G R Laking, MBChB, BMedSci1 and P M Price, MA, MD, FRCR2

1 Cancer Research UK PET Oncology Group, Hammersmith Hospital, Du Cane Road, London W12 0NN and 2 Academic Department of Radiation Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK

Surrogate markers of clinical outcome are important in anticancer drug research, since clinical criteria of response develop only slowly and may be confounded by other processes than drug effect. The need for surrogate outcome markers is especially great with newer agents that may act by tumour stabilization as opposed to shrinkage. Neoplastic angiogenesis is associated with a number of detectable changes at molecular and microcirculatory levels. Therefore, direct study of angiogenic molecular biology and tumour circulation before during and after treatment may offer useful surrogate markers for vascular-targeted therapies. The main advantage of radiotracer imaging with positron emission tomography (PET) is its functional specificity. This article will review two main areas: (a) the methodology behind PET imaging of tumour blood supply with 15O-oxygen labelled compounds; and (b) newer tracers in development as markers of angiogenetic biology.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. W. Xuan, M. Bygrave, H. Jiang, F. Valiyeva, J. Dunmore-Buyze, D. W. Holdsworth, J. I. Izawa, G. Bauman, M. Moussa, S. F. Winter, et al.
Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
Cancer Res., March 15, 2007; 67(6): 2830 - 2839.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. M. Provenzale
Imaging of Angiogenesis: Clinical Techniques and Novel Imaging Methods
Am. J. Roentgenol., January 1, 2007; 188(1): 11 - 23.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2003 by the British Institute of Radiology.